Factors contributing to erythropoietin hyporesponsiveness among hemodialysis patients: A cross-sectional multicenter study

6Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Background: Anemia resistant to erythropoietin stimulating agents (ESAs) is a risk factor for all-cause mortality. Determining the etiologies of hyporesponsiveness may help overcome the resistance. We investigated the contributing factors in a population of hemodialysis patients. Methods: In a multicenter cross-sectional study, from January 2015 to May 2015, point-prevalent hemodialysis patients from 22 dialysis centers in Tehran, Iran, were enrolled. Demographic, clinical, and laboratory data and drug history were recorded. ESA hyporesponsiveness index (EHRI) was calculated by dividing weekly ESA dose per kilogram of body weight (IU/Kg/W) by hemoglobin level (g/dL). Patients with EHRI≥ 16.49 (4th quartile) were compared with those with EHRI < 16.49 with respect to influential factors. Results: A total of 1224 patients were enrolled among whom, 306 (25%) had an EHRI ≥ 16.49 with a mean hemoglobin level of 9.8 ± 1.4 g/dL. There was no age, gender, or dialysis vintage difference within the groups. Iron status, parathormone, CRP, and diabetes were also similar. Hyporesponsive patients had lower body mass index (BMI) and lower serum albumin (P < 0.05). The proportion of patients who were treated with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) were significantly higher (P < 0.01) in hyporesponsive patients. In multivariate analysis, high doses of Venofer, high Kt/V, and high phosphate level were independently related to the presence of EHRI, and treatment with ACE/ARB was a marginally significant factor for EPO resistance. Conclusions: Apart from the most validated parameters responsible for ESA hyporesponsiveness (e.g. Iron deficiency, dialysis inadequacy, and poorly controlled serum phosphate level), other potential risk factors such as treatment with ACEi/ARB should be evaluated. Discontinuation of these drugs might be a therapeutic strategy to overcome ESA resistance.

References Powered by Scopus

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: A metaregression analysis

174Citations
N/AReaders
Get full text

Erythropoiesis-stimulating agent hyporesponsiveness (Review Article)

152Citations
N/AReaders
Get full text

Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients

151Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents

57Citations
N/AReaders
Get full text

Erythropoietin resistance in patients with chronic kidney disease: Current perspectives

32Citations
N/AReaders
Get full text

Melatonin improves erythropoietin hyporesponsiveness via suppression of inflammation

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Samavat, S., Nafar, M., Khoshdel, A., & Alipour-Abedi, B. (2017). Factors contributing to erythropoietin hyporesponsiveness among hemodialysis patients: A cross-sectional multicenter study. Nephro-Urology Monthly, 9(3). https://doi.org/10.5812/numonthly.45003

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

56%

Professor / Associate Prof. 3

33%

Lecturer / Post doc 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

75%

Pharmacology, Toxicology and Pharmaceut... 2

13%

Agricultural and Biological Sciences 1

6%

Nursing and Health Professions 1

6%

Save time finding and organizing research with Mendeley

Sign up for free